Type 2 Inflammation Biologic (Anti-IL-5) from GlaxoSmithKline (GSK).
Nucala is an IL-5 inhibitor used to treat conditions driven by eosinophilic inflammation. By reducing the number and activity of eosinophils, it substantially reduces asthma exacerbations, improves polyp burden, and is FDA-approved for several specific eosinophilic conditions.
Nucala is FDA-approved for the following indications:
Nucala is administered subcutaneously every four weeks. It is available as both an in-office injection and a self-administered auto-injector for appropriate patients.
The manufacturer offers a patient support program — GSK For You Patient Assistance — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.gskforyou.com.
Treatment with Nucala is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. This is a subcutaneous self-administered medication. After prior authorization, the prescription is sent to a specialty pharmacy that ships the medication directly to the patient. A manufacturer-sponsored nurse or office-based training visit is typically arranged for the first dose so patients are confident with self-administration before continuing at home.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.nucala.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Nucala is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.